



(86) Date de dépôt PCT/PCT Filing Date: 2013/07/29  
(87) Date publication PCT/PCT Publication Date: 2014/02/06  
(45) Date de délivrance/Issue Date: 2021/05/04  
(85) Entrée phase nationale/National Entry: 2015/01/27  
(86) N° demande PCT/PCT Application No.: EP 2013/065877  
(87) N° publication PCT/PCT Publication No.: 2014/019972  
(30) Priorité/Priority: 2012/08/03 (ES P 201231271)

(51) Cl.Int./Int.Cl. *A61K 9/00* (2006.01),  
*A61K 31/4196* (2006.01), *A61K 47/20* (2006.01),  
*A61K 9/10* (2006.01)  
(72) Inventeurs/Inventors:  
FRANCO RODRIGUEZ, GUILLERMO, ES;  
GUTIERRO ADURIZ, IBON, ES  
(73) Propriétaire/Owner:  
LABORATORIOS FARMACEUTICOS ROVI, S.A., ES  
(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : COMPOSITIONS INJECTABLES COMPRENANT DU LETROZOLE OU DE L'ANASTROZOLE  
(54) Title: INJECTABLE COMPOSITIONS COMPRISING LETROZOLE OR ANASTROZOLE

(57) Abrégé/Abstract:

The present invention refers to a composition suitable for forming an intramuscular implant comprising a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound, a kit suitable for the in situ formation of the composition and its use as a medicine for treating breast cancer.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 February 2014 (06.02.2014)

WIPO | PCT

(10) International Publication Number  
**WO 2014/019972 A1**

## (51) International Patent Classification:

*A61K 9/00* (2006.01) *A61K 9/10* (2006.01)  
*A61K 47/20* (2006.01) *A61K 31/4196* (2006.01)  
*A61K 47/34* (2006.01)

## (21) International Application Number:

PCT/EP2013/065877

## (22) International Filing Date:

29 July 2013 (29.07.2013)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

P 201231271 3 August 2012 (03.08.2012) ES

(71) Applicant: **LABORATORIOS FARMACÉUTICOS ROVI, S.A.** [ES/ES]; C/ Julián Camarillo, 35, E-28037 Madrid (ES).

(72) Inventors: **FRANCO RODRÍGUEZ, Guillermo**; C/ Julián Camarillo, 35, E-28037 Madrid (ES). **GUTIERRO ADURIZ, Ibon**; C/ Julián Camarillo, 35, E-28037 Madrid (ES).

(74) Agents: **ELZABURU MÁRQUEZ, Alberto de et al.**; c/ Miguel Angel, 21, 2º, E-28010 Madrid (ES).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

— with international search report (Art. 21(3))

(54) Title: INJECTABLE COMPOSITIONS COMPRISING LETROZOLE OR ANASTROZOLE

(57) Abstract: The present invention refers to a composition suitable for forming an intramuscular implant comprising a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound, a kit suitable for the in situ formation of the composition and its use as a medicine for treating breast cancer.



WO 2014/019972 A1

## INJECTABLE COMPOSITIONS COMPRISING LETROZOLE OR ANASTROZOLE

DESCRIPTIONFIELD AND OBJECT OF THE INVENTION

5 The present patent application is directed toward compositions useful in cancer therapies.

In particular, the present invention refers to a composition suitable for forming an intramuscular implant comprising a biodegradable thermoplastic polymer of polylactic acid (PLA), dimethyl sulfoxide (DMSO) and an aromatase inhibitor  
10 compound, a suitable kit for the *in situ* preparation of the composition and its use as a medicine for the treatment of breast cancer.

BACKGROUND

Without doubt, cancer treatments need to be developed, not only new molecular  
15 entities but also pharmacological products for improving patients' quality of life. In this sense, the development of prolonged release formulation signify an advance because they enable reducing the total dose administered, increasing the duration of each dose and the number of administrations and thereby create a positive impact on the emotional state of the patient.

20 In this sense, in the present invention, the active ingredients letrozole and anastrozole have been selected as candidate pharmaceutical drugs for this type of prolonged release formulation because they are the first line active ingredients in the adjuvant treatment of postmenopausal women with hormone receptor-positive advanced breast cancer for whom there is no alternative  
25 therapy beyond daily administration of a tablet.

Letrozole (4,4'-(1,2,4-triazol-1-ylmethyl)dibenzonitrile) and anastrozole (2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)) belong to a class of drugs called non-steroidal inhibitors of aromatase and their mechanism of action consists of reducing the amount of oestrogen in the body.

5 This effect can decelerate or stop the growth of many types of cancer-producing cells in the breast that need oestrogen to grow.

Currently there is no formulation of letrozole on the market with the ability to control the release of the drug over a long period of time. The pharmaceutical drug letrozole is currently only available in tablet form for daily oral  
10 administration. The formulations of letrozole described here enable obtaining therapeutic levels of the drug in blood from the start and continuously over a period of three months, avoiding the need for daily dosing regimes and thereby improving the patient's quality of life.

In the treatment of breast cancer, as in the treatment of cancer in general, the  
15 psychological state of the patient is very important; therefore the development of a three-monthly formulation of letrozole and/or anastrozole means a substantial improvement in their quality of life, reducing the impact that would result from daily treatment. In turn, medical examinations that are carried out during monitoring of the disease are normally conducted at 3 and 6 months over  
20 the first few years, so the administration of the formulation could coincide with consultancy visits to the doctor.

Similar reasoning has led to the appearance on the market of formulations such as Zoladex®, a preformed implant of goserelin for subcutaneous three-monthly application for the treatment of prostate carcinoma, and Implanon®, a  
25 preformed implant of etonogestrel used as a contraceptive. However, these preformed implants show a series of disadvantages including:

- The preparation of the implants by extrusion requires the use of high temperatures, which can cause the degradation of the active ingredient and the generation of potentially toxic impurities;

- Low homogeneity of the product obtained when including active ingredients at low doses;
- Need for surgical procedures for implanting or injection of the implant using large diameter needles.

5 It is also possible to find in the literature some publications on implantable compositions of letrozole and/or anastrozole such as the following:

For example, WO 2008/041245 describes implantable compositions comprising a wide variety of active ingredients such as some aromatase inhibitors, including anastrozole, in a wide variety of administration forms from preformed  
10 microparticles suspended in an aqueous vehicle to formulations that gellify *in situ*. Although it is doubtful that this document can sufficiently support all the combinations of active ingredients and administration forms that may arise, the examples always refer to preformed microparticles, that is it never describes systems of forming implants directly "*in situ*". Finally, it should be pointed out  
15 that none of the examples show a duration of over 60 days.

WO 2010/065358 A1 describes compositions for the administration of medicines containing testosterone and an aromatase inhibitor for continuous administration of testosterone and for preventing its conversion to estradiol. Although the description considers the possibility that the form of administration  
20 may be an implant, the only example of a form of administration is pellets.

Also, WO 2012/074883 A1 describes biodegradable compositions for administration of pharmaceutical drugs. These compositions require the use of water-insoluble solvents such as benzyl benzoate or benzyl alcohol in order to  
25 maintain the implant in a liquid or semi-solid state. These solvents have been previously shown to provide sudden releases and therefore are not suitable for the prolonged release compositions of the present invention.

Finally, US 2008/0206303 A1 describes prolonged release formulations of anastrozole comprising a PLA or PLGA polymer that can be accompanied by a wide variety of solvents; however, in the embodiments of the invention, the solvents used are benzyl alcohol and n-methyl-2-pyrrolidone (NMP), solvents that give rise to a very large burst followed by a subsequent almost zero release. In fact, the burst that was acceptable for the inventors in this document was 25-30% in one day, a very high value, and because of this none of their examples lasted more than 60 days; in particular in dogs, animals similar to humans, release did not continue longer than 35 days. Finally, no mention was made in this document of letrozole particle size nor of the importance of this factor in the behaviour of the formulation.

Therefore, it would be desirable to obtain a three-monthly formulation of letrozole and/or anastrozole for first line adjuvant treatment of breast cancer in hormone receptor-positive postmenopausal women. For this reason, the technology of implants of the invention that are formed *in situ* overcomes the majority of the drawbacks presented by current formulations based on preformed implants. It offers an alternative practical and effective therapy for the patient achieving therapeutic profiles lasting for at least 60 days.

#### DESCRIPTION OF THE FIGURES

The following figures are provided to help with the interpretation of the object of the present invention, but do not imply any limitation.

FIGURE 1: Figure 1 shows the plasma levels of letrozole (in ng/mL) obtained after intramuscular administration to New Zealand white rabbits of the formulations described in example 1. The values shown correspond to the mean plasma levels obtained in three animals of each group.

FIGURE 2: Figure 2 shows the plasma levels of letrozole (in ng/mL) obtained after the intramuscular administration to New Zealand white rabbits of the formulation described in example 2. The values shown correspond to the mean

plasma levels obtained in three animals of each group.

FIGURE 3: Figure 3 shows the plasma levels of letrozole (in ng/mL) obtained after intramuscular administration to New Zealand white rabbits of the formulations described in example 3. The values shown correspond to the mean plasma levels obtained in three animals of each group.

#### DETAILED DESCRIPTION OF THE INVENTION

For the composition that is the object of the present invention, the term initial "burst" is understood as the ratio of the area under the curve of plasma levels of the active ingredient in living animals obtained over the first 72 hours after intramuscular administration of the product to the total area under the curve (also termed "AUC") obtained after the injection of an amount of letrozole or anastrozole.

In order to obtain a prolonged release of active ingredient suitable for the object of the present invention, the area under the curve of the burst must be less than 10% compared to the total AUC, and ideally less than 5%. Similarly, obtaining an equilibrium in the prolonged release profile of the aromatase inhibitor over at least 60 days requires that no more than 50% of the area under the curve of plasma levels is obtained over the first 30 days after the injection. That is, for the object of the present invention, the preferred prolonged release of active ingredient is such that the area under the curve of the burst is less than 10% of the total AUC and not more than 50% of the total AUC is obtained over the first 30 days after injection.


For the object of the present invention, the following terms are used indistinctly:

"PLA"; "biodegradable thermoplastic polymer of polylactic acid"; "lactic polyacid" and "polylactic acid".



"DMSO" and "dimethyl sulphoxide".

6

Consequently, a first aspect of the invention is a composition suitable for forming an intramuscular implant comprising a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound of general formula (1):



wherein:



characterised in that the aromatase inhibitor compound is in suspension in a solution containing DMSO and PLA and represents between 15-50% by weight of the total composition, with the composition being able to solidify, to form a solid or gel-type implant on contact with an aqueous fluid or with that of the body, with therapeutic values after *in vivo* administration of at least 100 nmol/mL for more than 60 days.

Preferably, the aromatase inhibitor compound is in suspension in a solution containing DMSO and PLA and represents between 20-30% by weight of the total composition.



More preferably, the aromatase inhibitor compound is in suspension in a solution containing DMSO and PLA and is 25% by weight of the total composition.

5 According to another aspect, the aromatase inhibitor compound of general formula (1) has the following particle size distribution:

- < 10% of the particles less than 20 microns,
- < 10% of the particles greater than 350 microns and
- d<sub>0.5</sub> between 70-200 microns.

10 In a preferred embodiment, the aromatase inhibitor compound is letrozole or anastrozole, either alone or in combination.

In another preferred embodiment, the solution formed by DMSO and PLA has 40-43% by weight of PLA (100% lactic) + 57-60% by weight of DMSO.

In a further preferred embodiment, the terminal group of the PLA is as an ester instead of a carboxylic acid.

15 In another additional preferred embodiment, the active ingredient is subjected to sterilisation, for example by gamma or beta radiation. Sterilisation by radiation of the active ingredient may be carried out prior to its inclusion in the implantable composition to a maximum value of 35 kGy. Sterilisation of the active ingredient can also be carried out by terminal radiation of the product.

20 In a further preferred embodiment, the ratio of DMSO to letrozole is in the range of 0.5 to 3.7 and preferably in the range of 1.7 to 1.8.

In a still further preferred embodiment, the viscosity of the solution containing DMSO and PLA is in the range of between 0.8 and 1.8 Pa.s and preferably and preferably between 0.8 and 1.5 Pa.s, more preferably between 0.8 and 1.3 Pa.s  
25 and between 1.00 and 1.20 Pa.s.

In another additional embodiment, the maximum volume is 2 mL, allowing administration of 500 mg of letrozole by intramuscular injection.

A second aspect of the invention is the use of the composition above as a medicine for the treatment of breast cancer.

- 5 According to another aspect, the composition suitable for forming an intramuscular implant is characterised in that the AUC of the burst of the compound with the general formula (1) must be less than 10% of the total AUC and not more than 50% of the total AUC over the first 30 days after injection.

10 The final formulation can be prepared, for example, included in a syringe ready for use for intramuscular injection. The same formulation may form part, for example, of a kit of two syringes, one male and one female or two male syringes linked by a connector in which the solution of polymer in DMSO is in one syringe and the aromatase inhibitor is in solid form in a second syringe.

15 Similarly, the final composition can be obtained by, for example, maintaining one syringe with the polymer and aromatase inhibitor in solid state and the solvent in a second syringe.

20 Reconstitution in these cases is via direct joining of male and female syringes or by a connector where there are two male syringes, and the push-pull movement of the plungers in both directions giving rise to the combination of the products, and in this way to the solution of the polymer and the suspension of the active ingredient.

25 Any alternative to this system that gives rise to the composition of the present invention is possible, so that any variation with other designs of the formulation, where the final combination results in the desired product, for example maintaining the solvent or polymer solution in a vial apart from the active ingredient, or for example keeping the polymeric solution in a preloaded syringe and the aromatase inhibitor in a vial so that the polymeric solution is injected into the vial to give rise to the formation of the suspension, will be considered as possible alternatives for the object of the present invention.

Therefore, according to another aspect, the present invention refers to a suitable kit for the *in situ* preparation of the composition of the present invention, where the aromatase inhibitor compound of general formula (1) and the polymer are in a first container in solid form and the DMSO is in a second separate container.

Therefore, according to another aspect, the present invention refers to a suitable kit for the *in situ* preparation of the composition of the present invention where the polymer is lyophilised.

Therefore, according to another aspect, the present invention refers to a suitable kit for the *in situ* preparation of the composition of the present invention wherein the aromatase inhibitor compound of general formula (1) is in a first container in solid form and the DMSO and the polymer are in a second container in solution.

Therefore, according to another aspect, the present invention refers to a suitable kit for the *in situ* preparation of the composition of the present invention wherein the aromatase inhibitor compound of general formula (1), the polymer and the DMSO are in a single container in the form of a suspension.

Throughout the development of the present invention, the behaviour of various parameters that might have an influence on the result of the implantable compositions for prolonged release in accordance with the invention have been investigated. The parameters were the following:

*1. Rheological properties of the polymeric solutions and inherent viscosity*

The behaviour of the fluid, both of polymer solutions and the complete formulation, was evaluated by rheometry. In the case of matrices being considered as a vehicle for letrozole, these all have Newtonian behaviour. In the present document, viscosity is used as an indirect parameter and additional to the concentration of the polymer for the behaviour of the injectable formulation with respect to its ability to control the initial release of product.

Based on experimental work, it was determined that the polymer solution should have a minimum viscosity of 0.8 Pa.s, although this should preferably be around 1 Pa.s, but not greater than 1.8 Pa.s. Polymer solutions, in DMSO and measured at 25 °C, which are obtained within this viscosity range, provide the appropriate balance between solubilisation of the active ingredient and its retention in the polymeric matrix, thereby obtaining clinically relevant plasma concentrations of letrozole or anastrozole, avoiding release of excessive amounts of the active ingredient that may compromise the useful life of the implant during the diffusion phase of the active ingredient. When the active ingredient is added, the viscosity increases, but must not exceed the range of 3-4 Pa.s.

The following tables show the apparent viscosity of the most suitable polymers in their *in vitro* and *in vivo* behaviour at different concentrations in DMSO at 25 °C, as well as the viscosity of a final preferred formulation.

Viscosity of the PLA polymer Resomer® R 203 S, irradiated as raw material by beta radiation at a dose of 10 kGy,

Viscosity (Pa.s)	D,L -lactic polymer (% by w)			
	40%	41.5%	43%	45%
mean	0.874	1.020	1.295	1.645
SD	0.043	0.021	0.038	0.016

Viscosity of a preferred formulation

Viscosity (Pa.s)		
Replicated	mean	SD
2.462	2.514	0.045
2.536		
2.543		

## 2. Particle size of the active ingredient

The presence of the active ingredient in solution or in suspension critically affects the process of release of the active ingredient once the formulation is injected intramuscularly. Thus when letrozole is dissolved in the solution containing the polymer and DMSO, the intramuscular injection of the formulation gives rise to the release of an excessive amount over the first few days due to the diffusion of letrozole together with water-miscible solvent during the hardening process of the polymeric carrier, followed by a latency period in which *in vivo* release of the active ingredient is minimal and the final release of letrozole occurs at the time when the polymer experiences degradation by hydrolysis. The present document describes how only formulations containing letrozole in suspension are capable of controlling the initial release of the active ingredient and of preventing these periods of latency in which the formulation is not clinically effective. The particle size of the active ingredient therefore has a key effect in the final behaviour of the formulation as it directly affects the process of release from the formulation once it has been administered. The importance of this fundamental fact has not been previously described in documents describing the preparation of prolonged release formulations containing aromatase inhibitors.

Thus, the use of different size fractions was evaluated in order to determine or narrow an interval that is suitable and as well defined as possible. Better than a specific and totally narrow size, it is more useful to have a distribution of various crystal sizes enabling, to a certain extent, modulation of release in a staggered way. In this way, the smallest sizes are not useful because they very easily diffuse with the solvent during the formation of the implant (below 50 microns). Particles of intermediate sizes, with mean values close to 100-300 microns, can be more useful because they are retained by the matrix, require more time to dissolve and remain trapped in the implant during its solidification. Sizes above this require a high degree of degradation of the polymer, resulting in new latency periods in the life cycle of the implant and excessive releases at the time of hydrolysis of the polymer, the use of a high percentage in this size range not being particularly safe.

In a preferred embodiment, it has been determined that elimination not only of the smallest sizes but also of the intermediate to low sizes (50-100 microns) provides improvement to the product, given that, on the one hand, the final viscosity of the reconstituted product is reduced and, on the other hand, the pronounced burst effect is substantially prevented.

*3. Degree of suspension of the active ingredient in the solution containing the PLA and the DMSO.*

A characteristic of the present composition is that the aromatase inhibitor compound of general formula (1) is suspended, preferably present in an amount close to 25% by weight of the total composition, in a solution containing DMSO and PLA, which make up the remaining 75% by weight of the total composition.

This is not a random fact, but essential, because as will be seen later in example 1 if, for example, the formulation is in solution, the *in vivo* response is not satisfactory.

EXAMPLES

The following examples are illustrative of the invention and are not to be considered limiting.

Example 1: Study of the influence of the physical form of the active ingredient in the formulation: Suspension vs. Solution

The influence of the physical form of letrozole in the injectable solution (solution vs. suspension of the active ingredient) was evaluated by the use of the formulation described below:

## Formulation 1: formulation with letrozole in solution

Syringe 2.25 ml male	Ingredient	Amount (mg)
	Lactic acid polymer (ester terminal group) of intrinsic viscosity of 0.3 dl/g, irradiated as raw material at 10 kGy.	55.20
	Dimethyl sulphoxide	82.80
Syringe 2.25 ml female	Ingredient	Amount (mg)
	Letrozole	16.20

## Formulation 2: formulation with letrozole in suspension

Syringe 2.25 ml male	Ingredient	Amount (mg)
	Lactic acid polymer (ester terminal group) of intrinsic viscosity of 0.3 dl/g, irradiated as raw material at 10 kGy.	38.80
	Dimethyl sulphoxide	58.30
Syringe 2.25 ml female	Ingredient	Amount (mg)
	Letrozole	32.40

5

Letrozole particle size in formulation 2 was characterised by the technique of laser ray diffraction (Malvern Mastersizer 2000, suspended in water until obscuration of 9.41%) and had the following distribution (in % volume):  $d(0.1) = 38.21 \mu\text{m}$ ,  $d(0.5) = 141.35 \mu\text{m}$  and  $d(0.9) = 312.13 \mu\text{m}$ .

- 10 In both cases, reconstitution of the product was carried out by connection of the male and female syringes and successive movements of the plungers in both directions until complete solution of the polymer had been achieved.

Study of *in vivo* release in New Zealand white rabbits

- 15 Trials of *in vivo* release for the present document were carried out by determination of pharmacokinetic profiles of letrozole and anastrozole in plasma

after intramuscular administration in experimental animal models, rabbits and/or dogs.

For quantification of letrozole in dog and rabbit plasma a technique based on high performance liquid chromatography with fluorescence detector HPLC-FLD with mass-mass detector using a liquid-liquid extraction with ethylene acetate as the organic solvent and resuspension for analysis in reverse phase with isocratic elution. Carvedilol was used as the internal standard and the process time was 8.5 min with a letrozole retention time of 7.8 min and applying wavelengths of 240 nm ( $\lambda$  excitation) and 315 nm ( $\lambda$  emission). The validated concentration interval was from 5 (LLOQ) to 500 ng/mL, that is with a lower limit of quantification or minimum quantifiable analyte concentration of the analytical technique of 5 ng/mL and a maximum validated concentration of 500 ng/mL. Calibration curves obtained were characterised with a correlation coefficient of over 0.99. Precision and intra-assay and inter-assay accuracy was less than 20% for the LLOQ and less than 15% for the other QCs, that is, of the other known concentration samples used as quality controls in conducting the analysis. The bioanalytical method was validated over three days and the results met the acceptance criteria described in the FDA guide: "Bioanalytical Method Validation".

Samples of letrozole in dog and rabbit plasma were demonstrated to be stable at room temperature for up to 6 hours. Processed samples could be stored in the sampler at 4 °C for 24 hours without noticing any change in the precision and accuracy of the analysis. Cycles of freezing/thawing carried out did not affect the stability of letrozole in dog and rabbit plasma. Long term stability of the samples stored at -80 °C demonstrated stability for 132 days.

In the present example, formulations 1 and 2 were administered intramuscularly in the gluteus muscle of New Zealand white rabbits with approximate body weight of 3 kg. Three animals were used for each group and they were injected with an amount of formulation corresponding to 5.4 mg/kg for formulation 1 and 10.8 mg/kg for formulation 2. After injection, samples of plasma were collected



from the rabbits at previously established sampling times of up to 231 days after the injection. The results obtained are shown in Figure 1. Figure 1 shows that administration of the double dose of formulation 2 compared to formulation 1 in New Zealand white rabbits gave rise to similar initial plasma levels. Given that the dose used in formulation 1 was half that used in formulation 2, the clear importance of controlling the physical form of the active ingredient in the formulation could be seen. Letrozole, being in solution in formulation 1, diffuses with the solvent to a greater extent than in the case of letrozole in formulation 2. It can also be seen that in the case of formulation 1 the plasma levels fell swiftly, and did not start to recover until day 154 after injection, the time at which the active ingredient starts to be released due to the hydrolytic degradation of the polymer that retains it. Formulation 2 was able to maintain continuous significantly high levels of letrozole in rabbit plasma for more than 4 months.

#### Example 2: Study of the influence of the terminal group of the polymer

Evaluation of the influence of the terminal carboxylic or ester (N-capped) group of the polymer was evaluated by the use of the formulations described below:

Formulation 1: formulation of lactic acid polymer terminating in a carboxylic group

Syringe 2.25 ml male	Ingredient	Amount (mg)
	Lactic acid polymer (carboxylic terminal group) of intrinsic viscosity of 0.3 dl/g, irradiated as raw material at 10 kGy.	38.80
	Dimethyl sulphoxide	58.30
Syringe 2.25 ml female	Ingredient	Amount (mg)
	Letrozole	32.40

Formulation 2: formulation with lactic acid polymer terminating in an ester group

Syringe 2.25 ml male	Ingredient	Amount (mg)
	Lactic acid polymer (ester terminal group) of intrinsic viscosity of 0.3 dl/g, irradiated as raw material at 10 kGy.	38.80
	Dimethyl sulphoxide	58.30
Syringe 2.25 ml female	Ingredient	Amount (mg)
	Letrozole	32.40

5 Letrozole particle sizes in formulations 1 and 2 were characterised by the technique of laser ray diffraction (Malvern Mastersizer 2000, suspended in water until obscuration of 9.41%) and had the following distribution (in % volume):  $d(0.1) = 38.21 \mu\text{m}$ ,  $d(0.5) = 141.35 \mu\text{m}$  and  $d(0.9) = 312.13 \mu\text{m}$ .

In both cases, reconstitution of the product was carried out by connection of the male and female syringes and successive movements of the plungers in both directions until complete solution of the polymer had been achieved.

10 In parallel, the viscosity of the solution containing the components of the male syringe was evaluated, in amounts proportionally equivalent to those described (41.5% by weight of polymer with respect to the weight of solution) at 25 °C by the use of a rotational viscometer (Haake). The viscosity result values obtained are shown in the following table:

Polymer (beta irradiated at 10 kGy as raw material)	Viscosity at 25 °C (Pa.s)
PLA-carboxylic terminal group	1.221
PLA-ester terminal group	1.054

15

#### Study of *in vivo* release in New Zealand white rabbits

In the present example, formulations 1 and 2 were administered intramuscularly in the gluteus muscle of New Zealand white rabbits with approximate body weight of 3 kg. Three animals were used for each group and they were injected

with an amount of formulation corresponding to 10.8 mg/kg for both formulations. After injection, samples of plasma were collected from the rabbits at previously established sampling times of up to 175 days after injection. The results obtained are shown in Figure 2.

Figure 2 shows that administration of formulation 1 gave rise to very high initial letrozole plasma levels after injection. However, the levels progressively reduced until the levels were undetectable at 119 days. Formulation 2, on the other hand, resulted in significantly high levels over a clearly longer period of time. The high hydrophilicity of the polymer with the carboxylic terminal group and its higher wettability compared to the polymer with ester termination is probably behind the higher release of the active ingredient over the early phases of the study. Formulation 2, however, was able to modulate release of letrozole to a higher degree than formulation 1, giving rise to levels that were more sustainable over time. The % area under the curve of letrozole plasma levels in each formulation over the total area under the curve are shown in the following table:

Formulation	% AUC first 3 days	% AUC up to day 30	AUC total (ng h/ml)
1	3.981	66.630	328086.1
2	2.806	36.651	352267.6

### Example 3: Study of the influence of the terminal group of the polymer in Beagle dogs

Evaluation of the influence of the terminal carboxylic or ester (N-capped) group of the polymer was evaluated by the use of the formulations described below:

Formulation 1: formulation of lactic acid polymer terminating in a carboxylic group

Syringe 2.25 ml male	Ingredient	Amount (mg)
	Lactic acid polymer (carboxylic terminal group) of intrinsic viscosity of 0.3 dl/g, irradiated as raw material at 10 kGy.	107.6
	Dimethyl sulphoxide	151.7
Syringe 2.25 ml female	Ingredient	Amount (mg)
	Letrozole	86.5

Formulation 2: formulation with lactic acid polymer terminating in an ester group

Syringe 2.25 ml male	Ingredient	Amount (mg)
	Lactic acid polymer (ester terminal group) of intrinsic viscosity of 0.3 dl/g, irradiated as raw material at 10 kGy.	107.6
	Dimethyl sulphoxide	151.7
Syringe 2.25 ml female	Ingredient	Amount (mg)
	Letrozole	86.5

- 5 Letrozole particle sizes in formulations 1 and 2 were characterised by the technique of laser ray diffraction (Malvern Mastersizer 2000, suspended in water until obscuration of 9.41%) and had the following distribution (in % volume):  $d(0.1) = 38.21 \mu\text{m}$ ,  $d(0.5) = 141.35 \mu\text{m}$  and  $d(0.9) = 312.13 \mu\text{m}$ .

10 In both cases, reconstitution of the product was carried out by connection of the male and female syringes and successive movements of the plungers in both directions until complete solution of the polymer had been achieved.

The apparent viscosity at 25 °C of fully reconstituted formulation 2 gave a value of 2.865 Pa.s.

15 In parallel, the viscosity of the solution containing the components of the male syringe was evaluated, in amounts proportionally equivalent to those described (41.5% by weight of polymer with respect to the weight of solution) at 25 °C by

the use of a rotational viscometer (Haake). The viscosity result values obtained are shown in the following table:

Polymer (beta irradiated at 10 kGy as raw material)	Viscosity at 25 °C (Pa.s)
PLA-carboxylic terminal group	1.221
PLA-ester terminal group	1.054

#### Study of *in vivo* release in Beagle dogs

5 In the present example, formulations 1 and 2 were administered intramuscularly in the gluteus muscle of Beagle dogs with approximate body weight of 10 kg. Three animals were used for each group and they were injected with an amount of formulation corresponding to 86.5 mg/kg for both formulations. After injection, samples of plasma were collected from the dogs at previously established  
10 sampling times of up to 472 days after injection. The results obtained are shown in Figure 3.

Figure 3 shows that the difference observed in the previous example between the two polymers was significantly higher in dogs. The lower body temperature of the Beagle dog (some 2.4 °C lower than the New Zealand white rabbit)  
15 slowed down the diffusion process, probably due to a combination of effects between the lower speed of hydrolysis of the polymers at the lower temperature and lower diffusion of the active ingredient across the matrix also due to the lower body temperature. A higher influence of polymer hydrophilicity in the kinetic profile of letrozole was observed in this situation of reduced diffusion and  
20 speed of degradation. The observation of a continuous increase in letrozole plasma levels over the first 14 to 21 days demonstrates an enterohepatic circulation phenomenon that has been demonstrated by population pharmacokinetic analysis of the data obtained (Nonmen). This enterohepatic circulation of letrozole is likely to be also observable in humans. The % area  
25 under the curve of letrozole plasma levels in each formulation over the total area under the curve are shown in the following table:

Formulation	% AUC first 3 days	% AUC up to day 30	AUC total (ng h/ml)
1	1.527	74.963	460177.6
2	0.537	36.940	482879.8

## **CLAIMS**

1. Composition for forming an *in situ* intramuscular implant comprising a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound that is letrozole or anastrozole, either alone or in combination, **characterised in that** the aromatase inhibitor compound is in suspension in a solution containing DMSO and PLA and represents between 15-50% by weight of the total composition, where the composition solidifies to form a solid or gel-type *in situ* implant on contact with an aqueous or body fluid, and wherein the terminating group of the PLA is an ester.

2. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the aromatase inhibitor compound is in suspension in a solution containing DMSO and PLA and represents between 20-30% by weight of the total composition.

3. Composition for forming the *in situ* intramuscular implant according to any one of claims 1 to 2 **wherein** the aromatase inhibitor compound is in suspension in a solution containing DMSO and PLA and represents 25% by weight of the total composition.

4. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the aromatase inhibitor compound has the following particle size distribution in the formulation as measured by the technique of laser ray diffraction in water suspension until obscuration of 9.41%:

- < 10% of the particles less than 20 microns,
- < 10% of the particles greater than 350 microns and
- d0.5 between 70-200 microns.

5. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the solution containing DMSO and PLA is 40-43% by weight of 100% lactic PLA and 57-60% by weight of DMSO.

6. Composition for forming the *in situ* intramuscular implant according to any one

of claims 1 to 5 **wherein** the formulation is irradiated at a maximum value of 35 kGy.

7. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the weight ratio between DMSO and the aromatase inhibitor compound is in the range of 0.5 to 3.7.

8. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the weight ratio between DMSO and the aromatase inhibitor compound is in the range of 1.7 to 1.8.

9. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the viscosity of the solution containing DMSO and PLA is in the range between 0.8 and 1.8 Pa.s measured at 25 °C using a rotational viscometer.

10. Composition for forming the *in situ* intramuscular implant of claim 1 **wherein** the maximum volume of the composition is 2 mL containing 500 mg of letrozole for intramuscular injection.

11. Use of the composition according to any one of claims 1 to 10 as a medicine for treating breast cancer.

12. Kit for the *in situ* preparation of the composition according to any one of claims 1 to 10 wherein the aromatase inhibitor compound and the polymer in solid form are in a first container and the DMSO is in a second separate container.


13. Kit for the *in situ* preparation of an implant of claim 12 wherein the polymer is lyophilised.

14. Kit for the *in situ* preparation of the composition according to any one of claims 1 to 12 wherein the aromatase inhibitor compound is in a first container in solid form and the DMSO and the polymer are in a second container in solution.


15. Kit for the *in situ* preparation of the composition according to any one of claims 1 to 12 wherein the aromatase inhibitor compound, the polymer and the DMSO are in a single container in the form of a suspension.




1/3

**FIGURES****FIGURE 1**

2/3

**FIGURE 2**

3/3

**FIGURE 3**